Louis M. Staudt

97.5k total citations · 16 hit papers
293 papers, 34.8k citations indexed

About

Louis M. Staudt is a scholar working on Pathology and Forensic Medicine, Molecular Biology and Immunology. According to data from OpenAlex, Louis M. Staudt has authored 293 papers receiving a total of 34.8k indexed citations (citations by other indexed papers that have themselves been cited), including 146 papers in Pathology and Forensic Medicine, 110 papers in Molecular Biology and 102 papers in Immunology. Recurrent topics in Louis M. Staudt's work include Lymphoma Diagnosis and Treatment (138 papers), Chronic Lymphocytic Leukemia Research (80 papers) and Immune Cell Function and Interaction (44 papers). Louis M. Staudt is often cited by papers focused on Lymphoma Diagnosis and Treatment (138 papers), Chronic Lymphocytic Leukemia Research (80 papers) and Immune Cell Function and Interaction (44 papers). Louis M. Staudt collaborates with scholars based in United States, Germany and Canada. Louis M. Staudt's co-authors include Arthur L. Shaffer, Andreas Rosenwald, Xin Yu, R. Eric Davis, Wyndham H. Wilson, George W. Wright, Ryan M. Young, Patrick O. Brown, Georg Lenz and David Baltimore and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Louis M. Staudt

284 papers receiving 34.2k citations

Hit Papers

The Transcriptional Progr... 1984 2026 1998 2012 1999 2016 2001 2001 2002 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Transcriptional Program in the Response of Human Fibroblasts to Serum
    1999 1.6k citations Vishwanath R. Iyer, Michael B. Eisen et al. profile →
  2. Toward a Shared Vision for Cancer Genomic Data
    2016 1.1k citations Robert L. Grossman, Allison P. Heath et al. profile →
  3. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells
    2001 821 citations R. Eric Davis, Louis M. Staudt et al. profile →
  4. Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia
    2001 815 citations Andreas Rosenwald, Ash A. Alizadeh et al. profile →
  5. Blimp-1 Orchestrates Plasma Cell Differentiation by Extinguishing the Mature B Cell Gene Expression Program
    2002 799 citations Arthur L. Shaffer, Xin Yu et al. profile →
  6. XBP1, Downstream of Blimp-1, Expands the Secretory Apparatus and Other Organelles, and Increases Protein Synthesis in Plasma Cell Differentiation
    2004 793 citations Arthur L. Shaffer, Xin Yu et al. profile →
  7. A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo
    1990 781 citations Louis M. Staudt et al. profile →
  8. Control of Inflammation, Cytokine Expression, and Germinal Center Formation by BCL-6
    1997 776 citations Arthur L. Shaffer, Xin Yu et al. profile →
  9. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
    2003 701 citations George W. Wright, Andreas Rosenwald et al. profile →
  10. BCL-6 Represses Genes that Function in Lymphocyte Differentiation, Inflammation, and Cell Cycle Control
    2000 680 citations Arthur L. Shaffer, Xin Yu et al. profile →
  11. A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes
    1986 667 citations Louis M. Staudt et al. profile →
  12. JAKs and STATs in Immunity, Immunodeficiency, and Cancer
    2013 662 citations Louis M. Staudt et al. profile →
  13. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
    2020 583 citations George W. Wright, Da Wei Huang et al. Cancer Cell profile →
  14. IRF4 addiction in multiple myeloma
    2008 507 citations Arthur L. Shaffer, George W. Wright et al. profile →
  15. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin.
    1984 464 citations Louis M. Staudt et al. profile →
  16. Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
    2021 170 citations Wyndham H. Wilson, George W. Wright et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Louis M. Staudt United States 97 15.4k 11.3k 10.8k 9.4k 6.3k 293 34.8k
Riccardo Dalla‐Favera United States 113 16.4k 1.1× 13.0k 1.1× 15.2k 1.4× 14.4k 1.5× 9.3k 1.5× 300 40.4k
Scott J. Rodig United States 85 10.5k 0.7× 10.9k 1.0× 8.2k 0.8× 18.7k 2.0× 3.9k 0.6× 347 33.8k
Ash A. Alizadeh United States 66 15.5k 1.0× 10.6k 0.9× 4.7k 0.4× 11.0k 1.2× 2.8k 0.4× 251 35.5k
Thomas J. Kipps United States 91 11.7k 0.8× 14.8k 1.3× 13.2k 1.2× 7.6k 0.8× 19.7k 3.1× 622 35.2k
Peter Lichter Germany 100 19.4k 1.3× 5.3k 0.5× 7.5k 0.7× 6.7k 0.7× 11.9k 1.9× 490 36.6k
Axel Benner Germany 79 9.7k 0.6× 4.2k 0.4× 5.4k 0.5× 6.4k 0.7× 7.5k 1.2× 398 24.1k
John G. Gribben United Kingdom 89 5.0k 0.3× 10.9k 1.0× 8.8k 0.8× 8.4k 0.9× 9.2k 1.5× 481 24.1k
Ronald Levy United States 109 11.4k 0.7× 20.4k 1.8× 12.8k 1.2× 14.4k 1.5× 8.4k 1.3× 694 44.9k
Margaret A. Shipp United States 70 6.2k 0.4× 7.7k 0.7× 12.8k 1.2× 13.8k 1.5× 4.5k 0.7× 210 24.6k
William C. Hahn United States 101 26.5k 1.7× 4.7k 0.4× 2.5k 0.2× 11.2k 1.2× 2.5k 0.4× 293 40.9k

Countries citing papers authored by Louis M. Staudt

Since Specialization
Citations

This map shows the geographic impact of Louis M. Staudt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louis M. Staudt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louis M. Staudt more than expected).

Fields of papers citing papers by Louis M. Staudt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louis M. Staudt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louis M. Staudt. The network helps show where Louis M. Staudt may publish in the future.

Co-authorship network of co-authors of Louis M. Staudt

This figure shows the co-authorship network connecting the top 25 collaborators of Louis M. Staudt. A scholar is included among the top collaborators of Louis M. Staudt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louis M. Staudt. Louis M. Staudt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Xiaohu, Patricia Alfonso, Patrick J. Morris, et al.. (2025). An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors. PubMed Central. 8(12). 4312–4325.
2.
Melani, Christopher, Max J. Gordon, Stefania Pittaluga, et al.. (2024). Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies. Blood Cancer Discovery. 5(3_Supplement). PO–8.
3.
Wright, George W., Julius C. Enßle, Yandan Yang, et al.. (2024). Genetic Subclones Reveal Phenotypic Heterogeneity in Diffuse Large B-Cell Lymphoma. Blood. 144(Supplement 1). 451–451.
4.
Huang, Bonnie, James D. Phelan, Silvia Preite, et al.. (2022). In vivo CRISPR screens reveal a HIF-1α-mTOR-network regulates T follicular helper versus Th1 cells. Nature Communications. 13(1). 805–805. 23 indexed citations
5.
Wilson, Wyndham H., George W. Wright, Da Wei Huang, et al.. (2021). Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 39(12). 1643–1653.e3. 170 indexed citations breakdown →
6.
Zhang, Zhenyu, Kyle M. Hernandez, Jeremiah Savage, et al.. (2021). Uniform genomic data analysis in the NCI Genomic Data Commons. Nature Communications. 12(1). 1226–1226. 66 indexed citations
7.
Demajo, Santiago, Guillem Clot, Giancarlo Castellano, et al.. (2020). A Cyclin D1–Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical Cancer Research. 27(1). 213–225. 10 indexed citations
8.
Dadashian, Eman L., Erin M. McAuley, Delong Liu, et al.. (2018). TLR Signaling Is Activated in Lymph Node–Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. Cancer Research. 79(2). 360–371. 44 indexed citations
9.
Fitzsimons, Michael, Martin L. Ferguson, Allison P. Heath, et al.. (2017). Developing Cancer Informatics Applications and Tools Using the NCI Genomic Data Commons API. Cancer Research. 77(21). e15–e18. 26 indexed citations
10.
Jensen, Mark A., Vincent Ferretti, Robert L. Grossman, & Louis M. Staudt. (2017). The NCI Genomic Data Commons as an engine for precision medicine. Blood. 130(4). 453–459. 180 indexed citations
11.
Hathcock, Karen S., Hesed Padilla‐Nash, Jordi Camps, et al.. (2015). ATM deficiency promotes development of murine B-cell lymphomas that resemble diffuse large B-cell lymphoma in humans. Blood. 126(20). 2291–2301. 14 indexed citations
12.
Abrams, Jeffrey S., Barbara A. Conley, Margaret Mooney, et al.. (2014). National Cancer Institute's Precision Medicine Initiatives for the New National Clinical Trials Network. American Society of Clinical Oncology Educational Book. 71–76. 122 indexed citations
13.
Sanda, Takaomi, Lee N. Lawton, M. Inmaculada Barrasa, et al.. (2012). Core Transcriptional Regulatory Circuit Controlled by the TAL1 Complex in Human T Cell Acute Lymphoblastic Leukemia. Cancer Cell. 22(2). 209–221. 216 indexed citations
14.
Dunleavy, Kieron, Stefania Pittaluga, Myron S. Czuczman, et al.. (2009). Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 113(24). 6069–6076. 371 indexed citations
15.
Wilson, Wyndham H., Kieron Dunleavy, Stefania Pittaluga, et al.. (2008). Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. Journal of Clinical Oncology. 26(16). 2717–2724. 217 indexed citations
16.
Davis, R. Eric, Ya‐Qin Zhang, Noel Southall, et al.. (2007). A Cell-Based Assay for I κ B α Stabilization Using A Two-Color Dual Luciferase-Based Sensor. Assay and Drug Development Technologies. 5(1). 85–104. 21 indexed citations
17.
Park, Sung Sup, Arthur L. Shaffer, Joong Su Kim, et al.. (2005). Insertion of Myc into Igh Accelerates Peritoneal Plasmacytomas in Mice. Cancer Research. 65(17). 7644–7652. 19 indexed citations
18.
McConnell, Melanie J., Nathalie Chevallier, Windy Berkofsky‐Fessler, et al.. (2003). Growth Suppression by Acute PromyelocyticLeukemia-Associated Protein PLZF Is Mediated by Repression of c-myc Expression. Molecular and Cellular Biology. 23(24). 9375–9388. 111 indexed citations
19.
Rosenwald, Andreas & Louis M. Staudt. (2002). Clinical translation of gene expression profiling in lymphomas and leukemias. Seminars in Oncology. 29(3). 258–263. 36 indexed citations
20.
Botstein, David, Ash A. Alizadeh, Joseph L. DeRisi, et al.. (1998). DNA MICROARRAYS AS "MICROSCOPES" FOR WATCHING A GENOME IN ACTION. 21. 172. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Riccardo Dalla‐Favera Breakdown of academic impact, for papers by Scott J. Rodig Breakdown of academic impact, for papers by Ash A. Alizadeh Breakdown of academic impact, for papers by Thomas J. Kipps Breakdown of academic impact, for papers by Peter Lichter Breakdown of academic impact, for papers by Axel Benner Breakdown of academic impact, for papers by John G. Gribben Breakdown of academic impact, for papers by Ronald Levy Breakdown of academic impact, for papers by Margaret A. Shipp Breakdown of academic impact, for papers by William C. Hahn
Rankless by CCL
2026